INUS STUDIES

A controlled study of double filtration plasmapheresis in the treatment of active rheumatoid arthritis

Double filtration plasmapheresis for the treatment of a rheumatoid arthritis patient with extremely high level of c-reactive protein

Clinical improvement of Long-COVID is associated with reduction in autoantibodies, lipids, and inflammation following therapeutic apheresis

Removal of microparticles in blood plasma like chrome, lead, silicon, arsenic, aluminium and titanium with INUSpheresis treatment

Chronic post-COVID-19 syndrome
and chronic fatigue syndrome:

NUSpheresis could significantly reduce levels of neurotransmitter autoantibodies and alleviate symptoms of CFS

Metabolic and Non-Metabolic Peripheral Neuropathy:

Is there a Place for Therapeutic Apheresis?

Clinical Experience of Double Filtration Plasmapheresis for Drug Refractory Neurological Diseases

Experience of double filtration plasmapheresis in the treatment of Guillain-Barré syndrome

A Case Report of Double Filtration Plasmapheresis in an Acute Episode of Multiple Sclerosis

Double filtration plasmapheresis for the treatment of rheumatoid arthritis: a study of 21 cases

Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels

Patients were found to have a reduction in MACE of 83%

Alzheimer disease:

Following an Inuspheresis there was a significant reduction of proinflammatory lipids, circulating cytokines, immune complexes, proinflammatory metals and toxic chaperones in patients with AD

Plasmapheresis in acute phase of multiple sclerosis and neuromyelitis optica

Comparison between double-filtration plasmapheresis and immunoadsorption plasmapheresis in the treatment of patients with myasthenia gravis

Comparing the Autoantibody Levels and Clinical Efficacy of Double Filtration Plasmapheresis, Immunoadsorption, and Intravenous Immunoglobulin for the Treatment of Late-onset Myasthenia Gravis

Double filtration plasmapheresis benefits myasthenia gravis patients through an immunomodulatory action

Double filtration plasmapheresis in myasthenia gravis - analysis of clinical efficacy and prognostic parameters

Accelerating the Depletion of Circulating Anti-Phospholipase A2 Receptor Antibodies in Patients with Severe Membranous Nephropathy:

Preliminary Findings with Double Filtration Plasmapheresis and Ofatumumab

Double filtration plasmapheresis in the treatment of inflammatory polyneuropathy

Double filtration plasmapheresis: Review of current clinical applications